Journal article
Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction
KA Connelly, A Advani, S Advani, Y Zhang, K Thai, S Thomas, H Krum, DJ Kelly, RE Gilbert
Cardiovascular Therapeutics | Published : 2013
Abstract
Aims: Diminishing the activity of the renin-angiotensin system (RAS) plays a pivotal role in the treatment of heart failure. In addition to angiotensin converting enzyme (ACE) inhibitors and angiotensin-receptor blockers, direct renin inhibition has emerged as a potential adjunctive treatment to conventional RAS blockade. We sought to determine the effectiveness of this strategy after myocardial infarction (MI) in the setting of preexisting hypertension, a common premorbid condition in patients with ischemic heart disease. Methods and Results: Ten-week-old female heterozygous hypertensive (mRen-2)27 transgenic rats (Ren-2), were randomized to one of five groups (n = 8 per group); sham, MI, M..
View full abstractGrants
Awarded by NHMRC
Funding Acknowledgements
[ "This study was supported by a grant from Novartis Pharma and Canadian Institutes of Health Research. Ms. Christine Botelho provided invaluable expertise in animal handling. Dr. Kim Connelly was supported by a HSF Canada Phase 1 clinician scientist award, a TACTICS scholarship (Canada) and a NHMRC Neil Hamilton Fairley scholarship ID 440712. Dr. Richard Gilbert holds a Canada Research Chair in Diabetes Complications and this study was funded, in part, by the Canada Research Chair Program.", "Drs Krum, Gilbert, Kelly, Advani and Connelly have received research support and/or consulting fees from Novartis, the makers of Aliskiren." ]